Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 98 Carcinoma, Non-Small-Cell Lung 32 Neoplasms 22 Neoplasm Metastasis 14 Carcinoma, Renal Cell 13 Prostatic Neoplasms 12 Lung Neoplasms 12 Small Cell Lung Carcinoma 10 Diabetes Mellitus, Insulin-Dependent, 12 10 Pancreatic Neoplasms 7 Uveal Melanoma 6 Skin Neoplasms 6 Ovarian Neoplasms 6 Brain Neoplasms 6 Advanced Cancer 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Mesothelioma 5 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Kidney Neoplasms 4 Hodgkin Disease 4 Head and Neck Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma, Merkel Cell 4 Carcinoma, Hepatocellular 4 Carcinoma 4 Breast Neoplasms 4 Various Advanced Cancer 3

Interventions

rucaparib 1 relatlimab 1 linrodostat 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Gastric Cancer × Ipilimumab × Clear all

NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡